Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call on February 28, 2023, at 8:30 a.m. ET, to discuss its fourth quarter and full-year 2022 financial results and recent portfolio execution.
The call will be accessible via a live webcast on Kiniksa's website. Telephone participants must register to receive dial-in details. A replay will be available approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for critical unmet medical needs, with assets like ARCALYST and KPL-404 targeting cardiovascular and autoimmune conditions.
- Plans to report fourth quarter and full-year 2022 financial results, potentially highlighting growth.
- Focus on developing therapies for significant unmet medical needs, indicating potential for future revenue streams.
- None.
HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of immune-modulating assets, ARCALYST, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
| Every Second Counts! ® Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com |
FAQ
What is Kiniksa Pharmaceuticals planning to announce on February 28, 2023?
How can I access the Kiniksa Pharmaceuticals conference call?
What are Kiniksa's key products mentioned in the press release?
